Mood and cognitive disorders in cancer patients receiving cytokine therapy.
Abstract
Chronic treatment with cytokines is associated with the development of mood and cognitive changes that suggests frontal-subcortical cerebral dysfunction. There is large individual variability in the type and severity of specific symptoms that are reported. The CNS effects of cytokines can be disassociated from the effects of chronic disease, other treatments and medications, and psychological responses to illness. The length of treatment and dose are both important factors in the development of mood disturbance. The finding that treatment chronicity is important makes long-term follow-up of patients on cytokine therapy all the more vital. Most adverse effects of cytokines improve with appropriate treatment of symptoms, although dose reduction or cessation of therapy may be necessary in individual cases. Future studies will be needed to better identify at-risk individuals, to compare the efficacy of various interventions, including antidepressants, stimulants, and opiate antagonists, and to assess the feasibility of treating at-risk individuals prophylactically.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Administered in higher doses or during acute inflammation cytokines demonstrated detrimental effects on learning and memory.
“Administered in higher doses or during acute inflammation cytokines demonstrated detrimental effects on learning and memory [3], [54], [55].”
From Dose-dependent effects of endotoxin on neurobehavioral functions in humans (2011) · cites this paper as [54]
Cites
The American Journal of Gastroenterology
(2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.80003397.x · Cited by 2,203 · see citing works
Mood and cognitive side effects of interferon-alpha therapy.
Valentine, A. D., Meyers, C. A., Kling, M. A., Richelson, E., & Hauser, P. (1998) · PubMed · Cited by 312 · see citing works
Self-citationPersistent neurotoxicity of systemically administered interferon‐alpha
Meyers, C. A., Scheibel, R. S., & Forman, A. D. (1991) · Neurology · doi:10.1212/wnl.41.5.672 · Cited by 208 · see citing works
Self-citationPattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia
Pavol, M. A., Meyers, C. A., Rexer, J. L., Valentine, A. D., Mattis, P. J., & Talpaz, M. (1995) · Neurology · doi:10.1212/wnl.45.5.947 · Cited by 160 · see citing works
Self-citationTreatment of Neurotoxic Side Effects of Interferon-α with Naltrexone
Valentine, A. D., Meyers, C. A., & Talpaz, M. (1995) · Cancer Investigation · doi:10.3109/07357909509024923 · Cited by 137 · see citing works
Self-citationFluoxetine treatment of depression caused by interferon-alpha.
Levenson, J. L., & Fallon, H. J. (1993) · PubMed · Cited by 126 · see citing works
(1998) · PubMed · Cited by 121 · see citing works
Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes.
Licinio, J., Kling, M. A., & Hauser, P. (1998) · PubMed · Cited by 119 · see citing works
Cytokines and anorexia: a brief overview.
Plata‐Saláman, C. R. (1998) · PubMed · Cited by 101 · see citing works
Effects of interferon alpha on performance in man: a preliminary report
Smith, A. P., Tyrrell, D. A. J., Coyle, K. B., & Higgins, P. (1988) · Psychopharmacology · doi:10.1007/bf00216072 · Cited by 97 · see citing works
Cognitive functioning in cancer patients
Meyers, C. A., & Abbruzzese, J. L. (1992) · Neurology · doi:10.1212/wnl.42.2.434 · Cited by 85 · see citing works
Self-citationNeurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease
Meyers, C. A., Obbens, E. A. M. T., Scheibel, R. S., & Moser, R. P. (1991) · Cancer · doi:10.1002/1097-0142(19910701)68:1 · Cited by 76 · see citing works
Self-citationNeurological and Psychiatric Adverse Effects of Immunological Therapy
Meyers, C. A., & Valentine, A. D. (1995) · CNS Drugs · doi:10.2165/00023210-199503010-00006 · Cited by 72 · see citing works
Self-citationManic episodes in two patients treated with interferon alpha
Strite, D., Valentine, A. D., & Meyers, C. A. (1997) · Journal of Neuropsychiatry · doi:10.1176/jnp.9.2.273 · Cited by 64 · see citing works
Self-citationSuccessful Treatment of Interferon Alfa-Induced Mood Disorder With Nortriptyline
Goldman, L. S. (1994) · Psychosomatics · doi:10.1016/s0033-3182(94)71769-2 · Cited by 59 · see citing works
Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha.
Jones, T. H., Wadler, S., & Hupart, K. (1998) · PubMed · Cited by 59 · see citing works
Fatigue: definitions, mechanisms, and paradigms for study.
Mc, D., Mock, V., & Mj, H. (1998) · PubMed · Cited by 49 · see citing works
Delayed neurotoxicity of intraventricular interleukin-2: A case report
Meyers, C. A., & Yung, W. K. A. (1993) · Journal of Neuro-Oncology · doi:10.1007/bf01050073 · Cited by 30 · see citing works
Self-citationMapou, R. L., Law, W. A., Wagner, K., Malone, J. L., & Skillman, D. R. (1996) · Journal of Neuropsychiatry · doi:10.1176/jnp.8.1.74 · Cited by 27 · see citing works
Meyers, C. A., Valentine, A. D., Wong, F. C., & Leeds, N. E. (1994) · Journal of Neuropsychiatry · doi:10.1176/jnp.6.3.285 · Cited by 26 · see citing works
Self-citationAmato, R. J., Meyers, C., Ellerhorst, J. A., Finn, L. D., Kilbourn, R. G., Sella, A., & Logothetis, C. J. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059358 · Cited by 18 · see citing works
Self-citationThe opioid mechanism of interferon-α action
HO, B. T., Lu, J.-T., Huo, Y.-Y., Fan, S.-H., Meyers, C. A., Tansey, L. W., Payne, R., & Levin, V. A. (1994) · Anti-Cancer Drugs · doi:10.1097/00001813-199402000-00014 · Cited by 9 · see citing works
Self-citation
Flagged first, then by citations
1 of the 23 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766 · see citing works
“Although empirical support for the “sickness behavior model” of depression is more extensive in the animal literature, similar effects have been demonstrated in humans (76,77).”
ResultCytokine-Associated Emotional and Cognitive Disturbances in Humans
Reichenberg, A., Yirmiya, R., Schuld, A., Kraus, T., Haack, M., Morag, A., & Pollmächer, T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.445 · Cited by 1,365 · see citing works
Cytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235 · see citing works
“It has been suggested that cytokine inhibitors, besides exerting anti-inflammatory effects, might also be capable of attenuating depressive symptoms that accompany IRS activation in these and other medical conditions (Dantzer et al., 1999a; Meyers, 1999; Yirmiya et al., 1999).”
BackgroundInfluentialCytokine-induced sickness behavior: where do we stand?
Dantzer, R. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0613 · Cited by 862 · see citing works
Inflammation-associated depression: From serotonin to kynurenine
Dantzer, R., O’Connor, J. C., Lawson, M. A., & Kelley, K. W. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.09.012 · Cited by 726 · see citing works
“Besides these early correlative findings, the basic assumption that immune activation can cause depression stemmed from studies of cognitive and mood disorders in cancer patients receiving cytokine therapy (Meyers, 1999).”
BackgroundGiese-Davis, J., Collie, K., Rancourt, K. M. S., Neri, E., Kraemer, H. C., & Spiegel, D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4455 · Cited by 458 · see citing works
Cytokines as mediators of depression: what can we learn from animal studies?
Dunn, A. J., Swiergiel, A. H., & Beaurepaire, R. D. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.023 · Cited by 459 · see citing works
“Clinical research has shown that cytokine administration (IFNa and IL-2) in cancer patients can affect cognitive functions, with effects reminiscent of the dysfunctions observed in neurodegenerative diseases (Meyers, 1999).”
BackgroundSbarra, D. A., & Hazan, C. (2008) · Personality and Social Psychology Review · doi:10.1177/1088868308315702 · Cited by 427 · see citing works
“Moreover, malaise, fatigue, and apathy are among the cardinal symptoms of both depression and sickness (Dantzer, 2001; Dantzer, Wollman, & Yirmiya, 1999; Meyers, 1999).”
Anisman, H., Merali, Z., & Hayley, S. P. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.01.004 · Cited by 334 · see citing works
“, 1987) displayed cognitive disturbances, retarded cognitive processing and impaired executive functioning, impaired concentration and memory, irritability, and anxiety, as well as manic periods (Constant et al., 2005; Dieperink et al., 2003; Hilsabeck et al., 2005; Lieb et al., 2006; Meyers, 1999; Meyers and Valentin…”
Effects of cytokines and infections on brain neurochemistry
Dunn, A. J. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.04.002 · Cited by 336 · see citing works
“It has also been speculated that this could account for the depression-inducing properties of the interferons observed clinically [115].”
Won, E., & Kim, Y.-K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208113006 · Cited by 300 · see citing works
“Subsequent studies on depression in cancer patients receiving cytokine therapy supported the assumption that immune activation can cause depression [44-46].”
BackgroundIllness, Cytokines, and Depression
YIRMIYA, R., POLLAK, Y., MORAG, M., REICHENBERG, A., BARAK, O., AVITSUR, R., SHAVIT, Y., OVADIA, H., WEIDENFELD, J., MORAG, A., et al. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05412.x · Cited by 284 · see citing works
Cytokines and acute phase response in delirium
de Rooij, S. E., van Munster, B. C., Korevaar, J. C., & Levi, M. (2007) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2006.11.013 · Cited by 261 · see citing works
“In humans, a high-serum IL-6 and other cytokines have been associated with neuropsychiatric illness like cognitive decline in dementia [8] and in depression [9] and cognitive impairment and fatigue in cancer [10,11].”
BackgroundDose-dependent effects of endotoxin on neurobehavioral functions in humans
Grigoleit, J.-S., Kullmann, J. S., Wolf, O. T., Hammes, F., Wegner, A., Jablonowski, S., Engler, H., Gizewski, E., Oberbeck, R., & Schedlowski, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028330 · Cited by 241 · see citing works
“Administered in higher doses or during acute inflammation cytokines demonstrated detrimental effects on learning and memory [3,54,55].”
BackgroundCognitive function after chemotherapy in adults with solid tumours
Vardy, J. L., & Tannock, I. F. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.06.001 · Cited by 222 · see citing works
Pollak, Y., & Yirmiya, R. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003152 · Cited by 215 · see citing works
“Administration of cytokines (IL-2, IFN-a or TNF-a) causes influenza-like and depressive symptoms (Capuron et al., 2000; Meyers, 1999; Valentine et al., 1998).”
BackgroundToxoplasma gondii infection and behaviour – location, location, location?
McConkey, G. A., Martin, H. L., Bristow, G. C., & Webster, J. P. (2012) · Journal of Experimental Biology · doi:10.1242/jeb.074153 · Cited by 218 · see citing works
“These side effects are postulated to arise from IFN-γ-mediated induction of indoleamine-2,3dioxygenase (IDO) expression (Meyers, 1999) as IDO degrades tryptophan (Saito et al., 1991), the essential precursor of serotonin, and serotonin is involved in depressive disorders.”
BackgroundArgyriou, A. A., Assimakopoulos, K., Iconomou, G., Giannakopoulou, F., & Kalofonos, H. P. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2010.04.021 · Cited by 213 · see citing works
The hippocampus and TNF: Common links between chronic pain and depression
Fasick, V., Spengler, R. N., Samankan, S., Nader, N. D., & Ignatowski, T. A. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.03.014 · Cited by 205 · see citing works
“The findings that healthy volunteers administered TNF develop symptoms of depression (Dantzer et al., 1999; Meyers, 1999; Wichers and Maes, 2002), and as mentioned before, that TNF has been shown to be increased in patients experiencing chronic pain and depression, point toward TNF as a target for therapy.”
BackgroundSuarez, E. C., Krishnan, R. R., & Lewis, J. G. (2003) · Psychosomatic Medicine · doi:10.1097/01.psy.0000035719.79068.2b · Cited by 199 · see citing works
“Direct evidence for the behavioral effects of cytokines have mostly come from a number of animal studies (44) and studies of cancer patients (45).”
BackgroundMechanisms and Management of Toxicities Associated With High-Dose Interferon Alfa-2b Therapy
Kirkwood, J. M., Bender, C., Agarwala, S. S., Tarhini, A. A., Shipe-Spotloe, J. M., Smelko, B., Donnelly, S., & Stover, L. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.052 · Cited by 200 · see citing works
Saykin, A. J., Ahles, T. A., & McDonald, B. C. (2003) · PubMed · doi:10.1016/s1084-3612(03)00055-8 · Cited by 194 · see citing works
Low-dose endotoxemia and human neuropsychological functions
Krabbe, K. S., Reichenberg, A., Yirmiya, R., Smed, A., Pedersen, B. K., & Bruunsgaard, H. (2005) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2005.04.010 · Cited by 189 · see citing works
“Although not tested in a model of endotoxemia in humans, higher doses probably impair all types of memory as indicated by studies in which cancer patients have received cytokine therapy (Meyers, 1999) and by animal studies (Pugh et al.”
ResultCytokines and depression: fortuitous or causative association?
Dantzer, R., Wollman, E., Vitkovic, L., & Yirmiya, R. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000572 · Cited by 174 · see citing works
Ader, R. (2001) · Elsevier eBooks · doi:10.1016/b0-08-043076-7/03780-3 · Cited by 159 · see citing works
Capuron, L., Ravaud, A., & Dantzer, R. (2001) · Psychosomatic Medicine · doi:10.1097/00006842-200105000-00007 · Cited by 148 · see citing works
“A study of patients with chronic myelogenous leukemia treated with IFN-a showed that treated patients were less efficient in tests of cognitive speed, verbal memory, and executive functions than similar patients who had not undergone IFN-a therapy (15, 16).”
BackgroundResultAssociations between Melatonin, Neuroinflammation, and Brain Alterations in Depression
Won, E., Na, K., & Kim, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010305 · Cited by 146 · see citing works
Interferon-Induced Fatigue in Patients With Melanoma: A Pilot Study of Exercise and Methylphenidate
Schwartz, A. L., Thompson, J. A., & Masood, N. (2002) · Oncology nursing forum · doi:10.1188/02.onf.e85-e90 · Cited by 140 · see citing works
A Preliminary Study of Cytokines in Suicidal and Nonsuicidal Adolescents with Major Depression
Gabbay, V., Klein, R. G., Guttman, L. E., Babb, J. S., Alonso, C. M., Nishawala, M., Katz, Y., Gaite, M. R., & Gonzalez, C. J. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0140 · Cited by 136 · see citing works
“Clinical case reports worldwide have noted the emergence of depressive symptoms and death by suicide in patients treated with cytokines (Denicoff et al. 1987; Meyers 1999; Capuron et al. 2000; Capuron et al. 2001; Maes et al. 2001; Bonaccorso et al. 2002; Van Gool et al. 2003).”
Hauschild, A., Gogas, H. J., Tarhini, A. A., Middleton, M. R., Testori, A., Dréno, B., & Kirkwood, J. M. (2008) · Cancer · doi:10.1002/cncr.23251 · Cited by 129 · see citing works
“Nearly all patients develop adverse effects on memory after 6 doses of therapy.(29) Neuropsychiatric symptoms generally are mild to moderate and resolve within 2 to 3 weeks of IFN discontinuation.”
BackgroundReichenberg, A., Gorman, J. M., & Dieterich, D. T. (2005) · AIDS · doi:10.1097/01.aids.0000192087.64432.ae · Cited by 129 · see citing works
“Other studies have reported cognitive impairments in 5–17% of patients [6,13].”
BackgroundNovakovic, M. M., Korshunov, K. S., Grant, R. A., Martin, M. E., Abdala‐Valencia, H., Budinger, G. R. S., Radulović, J., & Prakriya, M. (2023) · Nature Communications · doi:10.1038/s41467-023-40968-6 · Cited by 128 · see citing works
“Studies have shown that deliberate injection of these and other cytokines in human subjects can induce feelings of anhedonia, fatigue, and helplessness 11 .”
The Impact of Medical Comorbidity on Acute Treatment in Major Depressive Disorder
Iosifescu, D. V., Nierenberg, A. A., Alpert, J. E., Smith, M., Bitran, S., Dording, C., & Fava, M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.12.2122 · Cited by 122 · see citing works
Distinguishing fatigue and depression in patients with cancer.
Jacobsen, P. B., Donovan, K. A., & Weitzner, M. A. (2003) · PubMed · doi:10.1016/s1084-3612(03)00049-2 · Cited by 122 · see citing works
Stress in schizophrenia: an integrative view
Wied, C. C. G. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00567-7 · Cited by 118 · see citing works
Further evidence for the depressive effects of cytokines: Anhedonia and neurochemical changes
Anisman, H., Kokkinidis, L., & Merali, Z. (2002) · Brain Behavior and Immunity · doi:10.1016/s0889-1591(02)00011-9 · Cited by 112 · see citing works
Depression, cytokines, and pancreatic cancer
Breitbart, W., Rosenfeld, B., Tobias, K., Pessin, H., Ku, G. Y., Yuan, J., & Wolchok, J. (2014) · Psycho-Oncology · doi:10.1002/pon.3422 · Cited by 106 · see citing works
“[5,25,26] Our findings, although preliminary, failed to support this hypothesized association.”
ResultCholinergic status modulations in human volunteers under acute inflammation
Ofek, K., Krabbe, K. S., Evron, T., Debecco, M., Nielsen, A. R., Brunnsgaad, H., Yirmiya, R., Soreq, H., & Pedersen, B. K. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0226-x · Cited by 106 · see citing works
“In healthy humans, endotoxin-induced cytokine secretion is correlated with impairments in verbal and non-verbal declarative memory functions [19], and similar findings were demonstrated in patients receiving cytokine immunotherapy for cancer or hepatitis-C [20].”
ResultDysthymia: a review of pharmacological and behavioral factors
Griffiths, J., Ravindran, A. V., Merali, Z., & Anisman, H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000697 · Cited by 96 · see citing works
Robson, M. J., Quinlan, M. A., & Blakely, R. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00412 · Cited by 95 · see citing works
Cohen, O., Reichenberg, A., Perry, C., Ginzberg, D., Pollmächer, T., Soreq, H., & Yirmiya, R. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:21:3:199 · Cited by 88 · see citing works
“Journal of Molecular Neuroscience 199 Volume 21, 2003”
BackgroundDepression in medical illness: The role of the immune system
Yirmiya, R. (2000) · Western Journal of Medicine · doi:10.1136/ewjm.173.5.333 · Cited by 83 · see citing works
Cognitive Function in Breast Cancer Survivors
Vardy, J. L. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-75115-3_24 · Cited by 77 · see citing works
Pollak, Y., Orion, E., Goshen, I., Ovadia, H., & Yirmiya, R. (2002) · Brain Behavior and Immunity · doi:10.1016/s0889-1591(02)00010-7 · Cited by 72 · see citing works
“Direct administration of IL-2 or interferons to human patients produces a depressive episode, which resolves immediately following termination of this immunotherapy (Capuron, Ravaud, & Dantzer, 2000; Dieperink et al., 2000; Meyers, 1999).”
BackgroundDarreh-Shori, T., Forsberg, A., Modiri, N., Andreasen, N., Blennow, K., Kamil, C., Ahmed, H., Almkvist, O., Långström, B., & Nordberg, A. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.028 · Cited by 64 · see citing works
Impact of medical comorbid disease on antidepressant treatment of major depressive disorder
Iosifescu, D. V., Bankier, B., & D, M. F. M. (2004) · Current Psychiatry Reports · doi:10.1007/s11920-004-0064-2 · Cited by 65 · see citing works
Lee, S. G., Lee, H. S., Lee, T.-B., Kim, D., Koo, J.-R., Kim, Y., & Son, B.-K. (2004) · Journal of Korean Medical Science · doi:10.3346/jkms.2004.19.3.384 · Cited by 57 · see citing works
“Experimental and clinical studies have indicated that these cytokines secreted excessively by stress might be one of the reasons for depression (16, 17).”
BackgroundIosifescu, D. V., Nierenberg, A. A., Alpert, J. E., Papakostas, G. I., Perlis, R. H., Sonawalla, S. B., & D, M. F. M. (2004) · Psychosomatics · doi:10.1176/appi.psy.45.5.419 · Cited by 54 · see citing works
Interleukin-2 potentiates novelty- and GBR 12909-induced exploratory activity
Zalcman, S. S. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02090-x · Cited by 55 · see citing works
Minding the body: Psychotherapy and cancer survival
Spiegel, D. (2014) · British Journal of Health Psychology · doi:10.1111/bjhp.12061 · Cited by 53 · see citing works
Darreh‐Shori, T., Modiri, N., Blennow, K., Baza, S., Kamil, C., Ahmed, H., Andreasen, N., & Nordberg, A. K. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.015 · Cited by 53 · see citing works
Overman, C. L., Bossema, E. R., van Middendorp, H., Meij, L. W., Verstappen, S. M. M., Bulder, M., Jacobs, J. W. G., Bijlsma, J. W. J., & Geenen, R. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200338 · Cited by 51 · see citing works
Treating Depression in the Medically Ill
Iosifescu, D. V. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.12.008 · Cited by 50 · see citing works
Banks, W., Niehoff, M., & Zalcman, S. (2004) · Brain, behavior, and immunity · doi:10.1016/j.bbi.2003.09.013 · Cited by 54 · see citing works
Mamalakis, G., Kiriakakis, M., Tsibinos, G., & Kafatos, A. (2004) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2003.10.005 · Cited by 46 · see citing works
Evolutionary Perspectives on Genetic and Environmental Risk Factors for Psychiatric Disorders
Keller, M. C. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084854 · Cited by 46 · see citing works
“Carefully controlled experiments, quasi-experiments, and observational studies (Capuron et al. 2000, 2004; Meyers 1999; Wright et al. 2005; Yirmiya et al. 2000) show that the body’s own defense response—specifically, proteins secreted by cells of the immune system called cytokines—cause this…”
MethodSi̇pahi̇, H., Mat, A. F., Özhan, Y., & Aydın, A. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666221223111309 · Cited by 45 · see citing works
Effect of Interferon-α on cognitive functioning in patients with chronic hepatitis C
HILSABECK, R. C., HASSANEIN, T. I., ZIEGLER, E. A., CARLSON, M. D., & PERRY, W. (2005) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617705050022 · Cited by 40 · see citing works
“…deficits remit within 2–3 weeks of discontinuation of IFN-a therapy (Mattson et al., 1984; Valentine et al., 1998), although there are reports by Meyers (1999) and Meyers and colleagues (1991b) that neuropsychological dysfunction persisted for months and years after therapy discontinuation in…”
BackgroundPsychological and behavioural effects of interferons
Bonaccorso, S., Meltzer, H. Y., & Maes, M. H. J. (2000) · Current Opinion in Psychiatry · doi:10.1097/00001504-200011000-00034 · Cited by 38 · see citing works
Questions raised by the cytokine hypothesis of depression
de Beaurepaire, R. (2002) · Brain, Behavior, and Immunity · doi:10.1016/s0889-1591(02)00005-3 · Cited by 39 · see citing works
Varghese, S. M., Patel, S., Nandan, A., Jose, A., Ghosh, S., Sah, R. K., Menon, B., Athira, K. V., & Chakravarty, S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04205-5 · Cited by 37 · see citing works
“Immuno-therapy for cancer and chronic hepatitis C that involves the administration of cytokines such as IL-2, TNF-α, and IFN-α is also reported to produce depressive symptoms [226, 227].”
Song, C., Luchtman, D. W., Kang, Z., Tam, E. M., Yatham, L. N., Su, K., & Lam, R. W. M. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.06.003 · Cited by 35 · see citing works
“patients (Meyers, 1999; Capuron et al., 2000).”
Cytokines and sickness behavior: Implications for cancer care and control
Miller, A. H. (2003) · Brain Behavior and Immunity · doi:10.1016/s0889-1591(02)00080-6 · Cited by 33 · see citing works
Personalized Medicine Using Neuroimmunological Biomarkers in Depressive Disorders
Chi, S., & Lee, M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020114 · Cited by 32 · see citing works
“Mixed IL-6 Mixed results [5,15] Yes [9] Decrease [11,13,15] IL-22 Increase [12] IFN-α Yes [23] -”
BackgroundMethodKrishna, S., Dodd, C. A., & Filipov, N. M. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.01.038 · Cited by 30 · see citing works
“undergoing cytokine (IL-2 or IFN) treatment [83].”
Astrocytic TNFα regulates the behavioral response to antidepressants
Duseja, R., Heir, R., Lewitus, G. M., Altimimi, H. F., & Stellwagen, D. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.09.012 · Cited by 25 · see citing works
“Cytokine-based therapies also lead to depressive symptomology (Meyers, 1999), which can be alleviated by antidepressants (Capuron et al., 2002).”
BackgroundCentral metabolite changes and activation of microglia after peripheral interleukin-2 challenge
Schneider, P., Weber‐Fahr, W., Schweinfurth, N., Ho, Y., Sartorius, A., Spanagel, R., & Pawlak, C. R. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.09.011 · Cited by 25 · see citing works
Benveniste, H., Zhang, S., Reinsel, R. A., Li, H., Lee, H., Rebecchi, M. J., Moore, W., Johansen, C., Rothman, D. L., & Bilfinger, T. V. (2012) · Europe PMC (PubMed Central) · Cited by 20 · see citing works
Depression has a Strong Relationship to Alterations in the Immune, Endocrine and Neural System
Hestad, K. A., Aukrust, P., Tønseth, S., & Reitan, S. K. (2009) · Current Psychiatry Reviews · doi:10.2174/157340009789542105 · Cited by 20 · see citing works
“In an animal model such depression-like symptoms following an immune response have been shown to be reduced by pretreatment with cytokine synthesis inhibitors and cytokine antagonists, or with cytokine gene manipulation (e.g. gene knockout) [8] [81] [82].”
BackgroundUnderstanding Cytokines Part II: Implications for Nursing Research and Practice
Corwin, E. J. (2000) · Biological Research For Nursing · doi:10.1177/109980040000200105 · Cited by 20 · see citing works
Does neuroimmune dysfunction mediate seasonal mood changes in winter depression?
Lam, R. W. M., Song, C., & Yatham, L. N. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.03.024 · Cited by 16 · see citing works
“Cytokines administered to healthy humans can induce depressive symptoms [69] and cancer patients often show depressive symptoms after receiving TNF-a or IFN-c treatment [70–73].”
BackgroundThe Contribution of TNFα to Synaptic Plasticity and Nervous System Function
Stellwagen, D. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6612-4_57 · Cited by 15 · see citing works
“Cytokine elevation, due to exogenous application or acute inflammation, leads to depressive symptomology in rodents [56, 57, 58] and humans [59, 60], which can be alleviated by anti-depressants [61].”
BackgroundNeuroendocrine–Immune Interactions: Implications for Health and Behavior
Pace, T. W. W., Raison, C. L., & Miller, A. H. (2009) · Elsevier eBooks · doi:10.1016/b978-008088783-8.00083-8 · Cited by 14 · see citing works
Psychoimmune Neuroendocrine Integrative Mechanisms Revisited
Cardinali, D. P., Cutrera, R. A., & Esquifino, A. I. (2000) · Neurosignals · doi:10.1159/000014643 · Cited by 14 · see citing works
The Cytokines and Depression Hypothesis: An Evaluation
Dunn, A. J. (2008) · Neuroimmune biology · doi:10.1016/s1567-7443(07)10023-5 · Cited by 8 · see citing works
Neuroimmune Mediators: Are Cytokines Mediators of Depression?
de Beaurepaire, R., Swiergiel, A. H., & Dunn, A. J. (2005) · Wiley eBooks · doi:10.1002/9783527619672.ch22 · Cited by 7 · see citing works
Cytokines in Synaptic Function
Ignatowski, T. A., & Spengler, R. N. (2008) · Neuroimmune biology · doi:10.1016/s1567-7443(07)10007-7 · Cited by 6 · see citing works
Chronic distress and the vulnerable host: a new target for HIV treatment and prevention?
Contoreggi, C. S., Chrousos, G. P., & Mascio, M. D. (2016) · Neurobehavioral HIV Medicine · doi:10.2147/nbhiv.s86309 · Cited by 6 · see citing works
Neuroendocrine-Immune Interactions
Raison, C. L., Gumnick, J. F., & Miller, A. H. (2002) · Elsevier eBooks · doi:10.1016/b978-012532104-4/50092-5 · Cited by 6 · see citing works
Cytokine-Induced Sickness Behavior and Depression
Chang, Q., Szegedi, S. S., O’Connor, J. C., Dantzer, R., & Kelley, K. W. (2008) · Springer eBooks · doi:10.1007/978-0-387-84851-8_9 · Cited by 5 · see citing works
Effects of the Immune System on Brain Neurochemistry
Dunn, A. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-30398-7_3 · Cited by 5 · see citing works
Kaur, G., & Salm, A. (2008) · Brain Research · doi:10.1016/j.brainres.2007.11.073 · Cited by 3 · see citing works
Madison, A. A., Andridge, R., Renna, M. E., Sheridan, J. F., Lustberg, M. B., Ramaswamy, B., Wesolowski, R., Williams, N. O., Sardesai, S. D., Noonan, A. M., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.09.008 · Cited by 3 · see citing works
Stress, Inflammation and Neurogenesis in Major Depression
Kim, Y. K. (2011) · Cited by 3 · see citing works
Physiological Markers in Anxiety and Depression
An, G. J., Jeong, J. S., Kim, Y. K., & Jeong, H. S. (2008) · Journal of Korean Biological Nursing Science · Cited by 3 · see citing works
Cytokines, Behavior, and Affective Disorders
Vellucci, S. V. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-384691-4.00012-2 · Cited by 2 · see citing works
Alves, G. J., & Palermo‐Neto, J. (2007) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 2 · see citing works
Maes, M. H. J., West, D. V., Nuyten, D. S. A., Neels, H. M., Vos, N. D., Bruyne, S. D., & Degroote, J. (2001) · Neuropsychobiology · doi:10.1159/000054868 · Cited by 1 · see citing works
Giraud, V., Rascle, N., & Ravaud, A. (2005) · Psycho-Oncologie · doi:10.1007/s10332-005-0085-z
Akademia Medyczna w Gdasku Zakøad Medycyny Paliatywnej
Buss, T. (2006)
The Impact of Medicalon Acute Treatment in Major Depressive Disorder
Iosifescu, D. V., Nierenberg, A. A., Alpert, J. E., Smith, M., Bitran, S., Dording, C. M., & D, M. F. M. (2005)
Cognitive effects of long-term interferon treatment for chronic viral hepatitis
Toni, E. D., Perini, G., Chemello, L., Mapelli, D., Bernardinello, E., Piccolo, F. D., Cavalletto, L., Bergamelli, C., Costanzo, R., Bergamaschi, F., et al. (2003) · Springer eBooks · doi:10.1007/978-94-010-0159-5_17
Fatigue and functioning in rheumatic diseases: a biopsychological perspective
Overman, C. L. (2015) · Utrecht University Repository (Utrecht University)
Men do better after myocardial infarction
(2000) · Western Journal of Medicine · doi:10.1136/ewjm.173.5.336
Molecular Biological Basis of Cognitive Disorders in Cancer
Tanrıverdi, Ö. (2022) · doi:10.69860/nobel.9786053358985.6
Molecular Aspects of Depressive Disorders
Sunzeri, F. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_8
- Authors
- Meyers, C. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Meyers, Christina A.
- Venue
- Advances in Experimental Medicine and Biology
- Publisher
- Springer US
- Published
- 1999
- Volume
- 461
- Pages
- 75-81
- ISSN
- 0065-2598 (ISSN-L)
- 2214-8019
- OpenAlex
- W206192302
- Cited by
- 98
- References
- 23
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 2 · 2018: 1 · 2017: 1 · 2016: 3 · 2015: 3 · 2014: 1 · 2013: 2 · 2012: 2
- FWCI
- 41.36
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Advances in experimental medicine and biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- cytokine therapy, mood disorders, cognitive impairment, cancer patients, treatment side effects, antidepressants, stimulants, opioid antagonists, prophylaxis
- MeSH terms
- Brain, Cognition Disorders, Humans, Neoplasms, Cytokines, Interferon-alpha, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
